In vitro effects of vandetanib on VEGFR2, EGFR and RET phosphorylation, endothelial cell tube formation, and tumor cell growth and survival

相似书籍

• Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
  由: Brave, SR, et al.
  出版: (2011)
• A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
  由: Pacey, S, et al.
  出版: (2016)
• Regulation of VEGFR3 signaling in lymphatic endothelial cells
  由: Kevin G. Kuonqui, et al.
  出版: (2025-02-01)
• Trafficking dynamics of VEGFR1, VEGFR2, and NRP1 in human endothelial cells.
  由: Sarvenaz Sarabipour, et al.
  出版: (2024-02-01)
• Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.
  由: Smith, N, et al.
  出版: (2010)